ANSWER: B

Rationale:

This question asked you to identify the signaling mechanism of the H2 receptor on the gastric parietal cell — the molecular target that H2 receptor antagonists block. The H2 receptor is a Gs-coupled receptor: when histamine binds, it activates adenylyl cyclase through the stimulatory G protein, raising intracellular cyclic AMP (cAMP). Elevated cAMP then activates protein kinase A, which stimulates the H+/K+-ATPase proton pump (the acid-secreting pump) on the apical membrane of the parietal cell. H2 antagonists compete with histamine at this receptor, reducing cAMP generation and thereby decreasing proton pump activity and acid output.

• Option A: Option A is incorrect because Gq-phospholipase C-IP3 signaling is the mechanism of the M3 muscarinic receptor and the CCK-2 (cholecystokinin) receptor on the parietal cell — not the H2 receptor; confusing these G protein coupling pathways is a common error.
• Option C: Option C is incorrect because Gi coupling (which inhibits adenylyl cyclase) describes the mechanism of prostaglandin E2 at EP3 receptors on the parietal cell, a cytoprotective pathway that reduces acid secretion — the H2 receptor is not Gi-coupled.
• Option D: Option D is incorrect because histamine receptors are G protein-coupled receptors, not ligand-gated ion channels; calcium influx through a channel is not the mechanism by which H2 receptor activation drives acid secretion.
• Option E: Option E is incorrect because receptor tyrosine kinases are the signaling mechanism for growth factors and cytokines such as EGF and insulin; histamine does not signal through a tyrosine kinase receptor on the parietal cell.

ANSWER: D

Rationale:

This question asked you to identify the structural basis for cimetidine's broad CYP inhibitory activity and why it places co-administered drugs at risk for toxicity. Cimetidine contains an imidazole ring whose nitrogen atom coordinates directly with the iron atom at the center of the cytochrome P450 heme group. This coordination competitively inhibits the enzyme's ability to oxidize its normal substrates. Because this mechanism applies across multiple CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), cimetidine simultaneously elevates plasma concentrations of warfarin (CYP2C9 substrate), phenytoin (CYP2C9/2C19), and theophylline (CYP1A2) — a clinically dangerous combination. Famotidine and nizatidine lack the imidazole ring and do not produce clinically meaningful CYP inhibition at therapeutic doses.

• Option A: Option A is incorrect because furan-ring-containing drugs such as some solvents can form reactive intermediates that inactivate CYP enzymes irreversibly — cimetidine does not contain a furan ring and its CYP inhibition is reversible and competitive.
• Option B: Option B is incorrect because benzimidazole rings are found in proton pump inhibitors (omeprazole, lansoprazole), not in cimetidine, and PPI CYP interactions are mediated by different and generally weaker mechanisms than cimetidine.
• Option C: Option C is incorrect because competitive substrate saturation is not the mechanism of cimetidine's CYP inhibition; it inhibits CYP via direct heme-iron coordination, not by acting as a preferred competing substrate in the traditional saturation sense.
• Option E: Option E is incorrect because thiourea-containing drugs can generate reactive sulfur intermediates capable of CYP inactivation, but cimetidine does not carry a thiourea group, and its inhibition is reversible and not bioactivation-dependent.

ANSWER: A

Rationale:

This question asked you to apply knowledge of the contrasting drug interaction profiles within the H2 receptor antagonist class to a specific clinical scenario. Famotidine is the correct choice because it does not contain the imidazole ring that is responsible for cimetidine's broad CYP inhibitory activity. As a result, famotidine does not inhibit CYP2C9 (which metabolizes warfarin and phenytoin) or other CYP isoforms at therapeutic doses, making it safe to co-administer with anticoagulants and antiepileptics without altering their plasma concentrations. The rule is: when an H2 receptor antagonist is clinically indicated in a patient on narrow-therapeutic-index drugs metabolized by CYP enzymes, famotidine (or nizatidine) is the correct choice, not cimetidine.

• Option B: Option B is incorrect because selecting cimetidine in this patient and managing with monitoring is not appropriate — monitoring does not eliminate the risk of warfarin-related hemorrhage or phenytoin toxicity from unpredictable CYP inhibition, and the interaction is avoidable by simply choosing a different agent.
• Option C: Option C is incorrect because ranitidine is no longer available in the United States due to N-nitrosodimethylamine (NDMA) contamination discovered in 2019 and was withdrawn from the market; it cannot be prescribed regardless of its interaction profile.
• Option D: Option D is incorrect because nizatidine would also be an acceptable choice (it lacks the imidazole ring and does not cause clinically significant CYP inhibition), but the statement that it "does not require renal dose adjustment in elderly patients" is false — nizatidine is renally eliminated and does require dose reduction in renal impairment, particularly in elderly patients where GFR is commonly reduced.
• Option E: Option E is incorrect because the mechanism of cimetidine's CYP inhibition is not dose-dependent in a way that makes low-dose cimetidine safe with warfarin and phenytoin; the imidazole-heme interaction occurs at therapeutic concentrations, and the other H2 receptor antagonists do not share this mechanism at any dose.

ANSWER: C

Rationale:

This question asked you to identify the clinically relevant onset advantage of H2 receptor antagonists over proton pump inhibitors in acute acid control. H2 receptor antagonists work by blocking the Gs-coupled H2 receptor on the parietal cell, reducing cAMP generation and decreasing proton pump activity — a mechanism that takes effect within 1–3 hours of administration regardless of whether the parietal cell is actively secreting acid at the time of dosing. PPIs, by contrast, are prodrugs that must be protonated and activated in the acidic secretory canaliculus of the actively secreting parietal cell; for this reason, PPIs are ideally taken 30–60 minutes before a meal when parietal cells are being stimulated and proton pumps are actively in the membrane. In urgent clinical situations requiring rapid acid suppression (including acute dyspepsia, nocturnal breakthrough, or intravenous acute use), H2RAs have a practical onset advantage.

• Option A: Option A is incorrect because this reverses the actual pharmacological relationship — H2RAs only block one of the three parietal cell stimulatory pathways (histamine via H2), whereas PPIs act at the final common step of the H+/K+-ATPase proton pump and thereby suppress acid secretion regardless of which pathway initiated it.
• Option B: Option B is incorrect because PPIs actually provide more sustained and complete acid suppression than H2RAs; H2RAs are subject to tolerance with continuous use as receptor upregulation occurs, and their duration of effect is shorter than the sustained 24-hour suppression achieved by PPIs.
• Option D: Option D is incorrect because PPIs, not H2RAs, produce superior healing of peptic ulcers — the evidence base for PPI superiority in peptic ulcer healing is well established, reflecting their more complete suppression of acid secretion from all stimulatory pathways.
• Option E: Option E is incorrect because the evidence for stress ulcer prophylaxis does not establish H2RA superiority over PPIs in either gastric pH elevation or bleeding rate reduction; both classes reduce clinically significant stress ulcer bleeding, and the choice between them in the ICU is guided by bleeding risk, route availability, and concerns about aspiration pneumonia with the alkaline gastric environment created by PPIs.

ANSWER: E

Rationale:

This question asked you to connect cimetidine's pharmacokinetics with its CNS adverse effect profile in the context of renal impairment. Cimetidine is significantly renally cleared, with a half-life of approximately 2 hours in normal renal function that extends substantially in patients with reduced GFR; dose reduction is required when GFR falls below 50 mL/min. At the GFR of 24 mL/min in this patient, standard dosing produces accumulation to plasma concentrations far above the therapeutic range. All H2 receptor antagonists cross the blood-brain barrier to varying degrees and can produce CNS adverse effects — including confusion, agitation, delirium, and hallucinations — at elevated plasma concentrations. Cimetidine is the most commonly implicated agent because it accumulates most readily in elderly patients with the renal impairment that is nearly universal in this population, and because its CNS adverse effects occur at plasma concentrations that are achieved with standard dosing in patients whose renal clearance is unrecognized or underdosed. This clinical scenario is a classic pharmacokinetics-clinical consequence pairing.

• Option A: Option A is incorrect because the mechanism of cimetidine's CNS toxicity is not related to blockade of central H2 receptors producing histamine excess; H2 receptor blockade in the CNS does not produce the agitation-confusion syndrome seen here, which is driven by drug accumulation, not by a central pharmacodynamic mechanism of the H2 antagonist itself.
• Option B: Option B is incorrect because while cimetidine does inhibit CYP2D6 (among other CYP isoforms), this does not cause catecholamine accumulation or explain the clinical picture of confusion and agitation; catecholamine metabolism in the CNS involves monoamine oxidase and catechol-O-methyltransferase, not CYP2D6.
• Option C: Option C is incorrect because cimetidine is not primarily hepatically cleared — it has significant renal elimination and requires dose adjustment for renal (not hepatic) impairment; this distinguishes it from drugs like midazolam or lidocaine where hepatic flow is the dominant clearance determinant.
• Option D: Option D is incorrect because cimetidine does not have clinically significant anticholinergic activity — the confusion and agitation in this patient are due to drug accumulation from renal impairment, not to muscarinic receptor blockade; anticholinergic syndrome would additionally produce dry mouth, urinary retention, dilated pupils, and tachycardia, which are not described.

ANSWER: B

Rationale:

This question asked you to apply cromolyn's mechanism of action to the clinical question of when it can and cannot be used. Cromolyn sodium stabilizes mast cells by interfering with calcium ion flux across the mast cell membrane that is required for granule-plasma membrane fusion during exocytosis. Because this action prevents degranulation from occurring, cromolyn has no utility once degranulation has already been triggered — histamine, leukotrienes, and other preformed or newly synthesized mediators have already been released by the time symptoms appear. Cromolyn therefore must be used prophylactically, before allergen exposure, and has no role as a rescue agent for an attack already in progress. The correct acute rescue agent is a short-acting beta-2 agonist (albuterol/salbutamol). Cromolyn does retain a role in exercise-induced bronchospasm prophylaxis when taken 15–20 minutes before exercise.

• Option A: Option A is incorrect because cromolyn does not block histamine receptors — it acts upstream of mediator release by stabilizing the mast cell; it has no antihistamine activity and cannot reverse the effects of histamine already released.
• Option C: Option C is incorrect because cromolyn does not block the H1 receptor at all — it is a mast cell stabilizer, not an antihistamine, and it has no direct bronchoconstrictor-reversing activity; the premise of the option is pharmacologically incorrect.
• Option D: Option D is incorrect because while cromolyn does have efficacy in exercise-induced bronchospasm prophylaxis, the reason is not that it preferentially inhibits thermal or osmotic triggers over allergen triggers — the mechanism of mast cell stabilization applies broadly, and the correct use is prophylactic administration before the triggering event regardless of trigger type.
• Option E: Option E is incorrect because cromolyn does not compete with IgE for Fc-epsilon-RI binding — its mechanism is intracellular calcium channel interference, not receptor competition; omalizumab is the agent that reduces free IgE and disrupts IgE-Fc-epsilon-RI interactions, and it acts on a completely different pharmacological target.

ANSWER: D

Rationale:

This question asked you to identify the specific molecular target of omalizumab and explain how that target produces its clinical effect. Omalizumab is a recombinant humanized IgG1 monoclonal antibody that binds to free circulating IgE at the Fc-epsilon-III domain — the exact region of IgE that would otherwise attach to the high-affinity Fc-epsilon-RI receptor on mast cells and basophils. By sequestering free IgE in circulation, omalizumab prevents IgE from occupying Fc-epsilon-RI on mast cell surfaces. Without surface-bound IgE, allergen cannot cross-link receptors and initiate the degranulation signal. A secondary effect develops over weeks to months: because Fc-epsilon-RI receptor expression on mast cells is upregulated by surface IgE occupancy, as free IgE falls and surface IgE diminishes, Fc-epsilon-RI receptor density also decreases, further reducing allergic reactivity.

• Option A: Option A is incorrect because omalizumab does not bind to the Fc-epsilon-RI receptor on mast cells — it binds to free IgE in the circulation before IgE reaches the mast cell; blocking the receptor directly would interfere with all IgE-mediated immune functions and is not the mechanism of this drug.
• Option B: Option B is incorrect because omalizumab does not target IL-4 or IL-13 — those cytokines are targeted by dupilumab (anti-IL-4 receptor alpha); the two drugs have different mechanisms and different target molecules despite both being used in allergic diseases.
• Option C: Option C is incorrect because omalizumab cannot bind to IgE that is already occupying Fc-epsilon-RI on mast cells — the Fc-epsilon-III domain is physically inaccessible (buried in the receptor binding interface) once IgE is receptor-bound; omalizumab therefore acts on free IgE before it reaches the receptor, not on receptor-bound IgE already present on sensitized mast cells.
• Option E: Option E is incorrect because tryptase is an enzyme released from mast cell granules that amplifies downstream inflammatory cascades; no approved agent targets tryptase, and omalizumab's mechanism is entirely upstream of degranulation — it prevents degranulation from being triggered, not its downstream amplification.

ANSWER: A

Rationale:

This question asked you to explain the mechanistic rationale for epinephrine's primacy in anaphylaxis — not just that it is first-line, but why no other single agent can substitute for it. The multimediator nature of anaphylaxis involves histamine, platelet-activating factor (PAF), prostaglandin D2, and cysteinyl leukotrienes driving vasodilation, increased permeability, and bronchospasm through multiple receptor systems simultaneously. Epinephrine addresses this complexity through three simultaneous actions: alpha-1 receptor-mediated vasoconstriction reverses the distributive hypotension; beta-2 receptor activation on bronchial smooth muscle reverses bronchospasm; and beta-2 receptor stimulation on mast cells and basophils raises intracellular cAMP, which inhibits ongoing degranulation and mediator release. Antihistamines block only the histamine-mediated components and have no effect on leukotriene-, PAF-, or prostaglandin-driven vasodilation and bronchospasm. Corticosteroids have a delayed onset of hours and address only the late-phase inflammatory response. Bronchodilators such as albuterol address only the airway component and do not reverse systemic vasodilation.

• Option B: Option B is incorrect because epinephrine does not block histamine receptors or leukotriene receptors — it is an adrenergic agonist, not a receptor antagonist for those mediator classes; its benefit comes from adrenergic receptor activation counteracting the downstream effects of those mediators, not from blocking their receptors.
• Option C: Option C is incorrect because while beta-1 activation does increase cardiac output and this contributes to hemodynamic support, framing beta-1 activation as the primary mechanism and relegating antihistamines to the bronchospasm role is incorrect — antihistamines do not reliably reverse bronchospasm in anaphylaxis, and the multimediator mechanism of epinephrine is not adequately captured by cardiac output elevation alone.
• Option D: Option D is incorrect because epinephrine does not work primarily by inhibiting phospholipase A2 synthesis — its mechanism is adrenergic receptor activation, not lipid mediator synthesis suppression; corticosteroids inhibit phospholipase A2 (through annexin/lipocortin induction), not epinephrine.
• Option E: Option E is incorrect because the basis for epinephrine's superiority over antihistamines and corticosteroids is mechanistic, not merely temporal — antihistamines and corticosteroids are not equally effective to epinephrine with a slower onset; they are structurally incapable of addressing the multimediator hemodynamic collapse of anaphylaxis regardless of how much time passes.

ANSWER: C

Rationale:

This question asked you to identify the correct administration site for epinephrine in anaphylaxis and the pharmacological basis for that preference. Intramuscular injection into the mid-outer thigh (vastus lateralis muscle) is the established standard of care. The vastus lateralis has high vascularity and, in most patients, less overlying subcutaneous fat than the deltoid — both factors that accelerate absorption and produce faster, higher, and more reliable peak plasma epinephrine concentrations compared to either subcutaneous injection or deltoid intramuscular injection. This is clinically critical: in anaphylaxis, peak concentration and time to peak concentration directly determine the speed of reversal of hemodynamic collapse and bronchospasm. Auto-injectors (EpiPen 0.3 mg for adults, EpiPen Jr 0.15 mg for children) are designed for thigh administration and constitute the standard outpatient self-administration device.

• Option A: Option A is incorrect because intravenous epinephrine is reserved for patients with cardiovascular collapse refractory to repeated intramuscular dosing — IV bolus of epinephrine at the 1:1000 concentration used for IM injection is dangerous, causing hypertensive crisis and potentially fatal arrhythmias; if IV epinephrine is used it requires the 1:10,000 dilution and continuous hemodynamic monitoring in a resuscitation setting.
• Option B: Option B is incorrect because subcutaneous epinephrine produces slower, lower, and less reliable absorption than intramuscular injection into the thigh — local vasoconstriction at the subcutaneous injection site (which epinephrine does produce via alpha-1 receptors) delays systemic absorption rather than creating a beneficial depot, making subcutaneous injection inferior to IM injection in the acute setting.
• Option D: Option D is incorrect because the deltoid has lower vascularity and more variable subcutaneous fat thickness than the vastus lateralis, producing slower and less reliable absorption; though the deltoid is anatomically accessible, studies comparing administration sites in anaphylaxis consistently demonstrate the superiority of vastus lateralis injection.
• Option E: Option E is incorrect because sublingual epinephrine does not provide absorption equivalent to intramuscular injection — sublingual mucosa absorption is variable and generally slower than IM injection in the mid-outer thigh; no sublingual epinephrine formulation is approved for anaphylaxis management, and this route is not established in any major guideline for acute anaphylaxis treatment.

ANSWER: E

Rationale:

This question asked you to explain the specific mechanism by which glucagon rescues anaphylaxis in patients whose beta-adrenergic receptors are pharmacologically blocked. Beta-blockers such as metoprolol occupy beta-adrenergic receptors and prevent epinephrine from activating them; this blocks epinephrine's beta-1-mediated increase in cardiac output and chronotropy as well as its beta-2-mediated bronchodilation, leaving only alpha-1 vasoconstriction intact from the epinephrine dose. The result is refractory bronchospasm, bradycardia, and hypotension. Glucagon rescues this situation because it acts on its own dedicated G protein-coupled glucagon receptor (separate from the beta-adrenergic receptor), which activates adenylyl cyclase and raises intracellular cAMP in cardiac myocytes and bronchial smooth muscle through a beta-receptor-independent pathway. This cAMP elevation restores positive inotropy, chronotropy, and some degree of bronchodilation despite complete occupancy of beta receptors by metoprolol. The intravenous dose is 1–5 mg bolus followed by infusion at 5–15 micrograms/min. Nausea and vomiting are common adverse effects requiring aspiration precautions.

• Option A: Option A is incorrect because glucagon is not a beta-adrenergic receptor partial agonist and does not compete with beta-blockers for receptor occupancy — its receptor is distinct from the beta-adrenergic receptor; displacing a competitive beta-blocker would in any case require extremely high glucagon concentrations far beyond the therapeutic range.
• Option B: Option B is incorrect because glucagon does not activate alpha-1 adrenergic receptors — its receptor is the glucagon receptor, a distinct GPCR; glucagon's cardiovascular effects are driven by cAMP elevation through its own receptor pathway, not by alpha-1 receptor cross-reactivity.
• Option C: Option C is incorrect because glucagon is not an antihistamine and does not interact with glucocorticoid-sensitive pathways — corticosteroids (not glucagon) act through glucocorticoid receptors; the mechanism described is pharmacologically fictitious and conflates glucagon with glucocorticoids.
• Option D: Option D is incorrect because glucagon is not a phosphodiesterase inhibitor — milrinone and theophylline inhibit phosphodiesterase to elevate cAMP; glucagon raises cAMP by activating adenylyl cyclase through its G protein-coupled receptor, which is a different mechanism at a different molecular step in the cAMP pathway.

ANSWER: B

Rationale:

This question asked you to explain the mechanistic basis for combined H1 plus H2 antihistamine use in anaphylaxis — a standard adjunctive regimen that requires understanding the distinct receptor distribution of H1 and H2 across tissues. H1 receptors are expressed on vascular endothelial cells and vascular smooth muscle, where histamine binding produces vasodilation, increased vascular permeability, urticaria, and angioedema. H2 receptors are expressed on gastric parietal cells (their classical location) but also on cardiac myocytes, where histamine binding contributes to tachycardia, and in some peripheral vascular beds, where H2 receptor-mediated vasodilation supplements H1-mediated vasodilation. Diphenhydramine alone blocks only H1-mediated effects; adding famotidine provides blockade of the H2-mediated cardiac and additional vascular components of histamine's hemodynamic effects. Observational evidence supports this combination for addressing the cutaneous and hemodynamic manifestations of anaphylaxis, though neither agent alone or in combination substitutes for epinephrine as the primary treatment.

• Option A: Option A is incorrect because H1 receptor blockade does not require supplementation due to receptor saturation during histamine surges — antihistamines work by competitive antagonism and the issue is not insufficient H1 receptor occupancy by diphenhydramine, but rather that H2 receptors in cardiac and vascular tissue are simply outside diphenhydramine's pharmacological reach.
• Option C: Option C is incorrect because famotidine does not penetrate mast cells or stabilize them against degranulation — it is a competitive H2 receptor antagonist that blocks histamine at the extracellular receptor, just like diphenhydramine at H1 receptors; mast cell stabilization is the mechanism of cromolyn and nedocromil, not H2 antagonists.
• Option D: Option D is incorrect because preventing gastric acid secretion during anaphylaxis is not the rationale for adding H2 blockers to the acute anaphylaxis regimen; while H2 receptors are present on parietal cells, the clinical goal of H2 blockade in anaphylaxis is hemodynamic (cardiac and vascular receptor coverage), not gastric acid prevention.
• Option E: Option E is incorrect because H1 and H2 receptors are distinct receptor proteins encoded by different genes; there is no allosteric interaction or shared receptor dimer between H1 and H2 receptors — they do not potentiate each other's binding affinity, and the pharmacological basis for combining them is anatomical receptor distribution, not synergistic receptor binding.

ANSWER: D

Rationale:

This question asked you to identify a fundamental distinction in how bradykinin is generated compared to histamine — a comparison that has direct clinical consequences for how their respective pathological effects are managed. Histamine is synthesized in advance by decarboxylation of histidine, packaged in mast cell (and basophil) secretory granules, and released rapidly by exocytosis when the cell is activated — the release is immediate because the mediator is already made and waiting. Bradykinin, by contrast, is not stored anywhere in preformed or inactive form in a granule. It is generated on demand from high-molecular-weight kininogen (HMWK), a plasma protein, through a sequential protease cascade: factor XII activation leads to plasma kallikrein formation, which cleaves HMWK to release bradykinin. This cascade is triggered by tissue injury, contact with foreign surfaces, or inflammation, and bradykinin acts locally and transiently before its extremely rapid degradation by angiotensin-converting enzyme (kininase II) and carboxypeptidase N, with a plasma half-life of approximately 15–30 seconds. This distinction explains why epinephrine and antihistamines effectively reverse histamine-mediated effects but have limited efficacy against bradykinin-mediated pathology — they target histamine receptors, not the kallikrein-kinin protease cascade.

• Option A: Option A is incorrect because bradykinin is not stored in mast cell granules — it is a circulating-plasma-protein-derived peptide generated by enzymatic cleavage, not a preformed granule mediator; its plasma half-life is approximately 15–30 seconds, not 4–6 minutes.
• Option B: Option B is incorrect because bradykinin is not produced by basophils through a direct synthetic pathway — it is generated from HMWK by plasma and tissue kallikreins through proteolytic cleavage; the synthesis pathway requires the sequential activation of factor XII and prekallikrein, which are plasma proteins, not intracellular basophil enzymes.
• Option C: Option C is incorrect because bradykinin is not stored in vascular endothelial cells — the kinin precursor HMWK circulates in plasma and the cascade is activated extracellularly, not by endothelial exocytosis; bradykinin generation is driven by plasma-phase protease activity, not cell-mediated secretory events.
• Option E: Option E is incorrect because bradykinin is a peptide (a nonapeptide: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), not a lipid mediator — it is not derived from the arachidonic acid pathway; leukotrienes and prostaglandins are the lipid mediators generated from arachidonate after mast cell degranulation, and bradykinin is structurally and biosynthetically entirely distinct from this pathway.

ANSWER: A

Rationale:

This question asked you to identify the correct sequence of the plasma kallikrein-kinin cascade that generates bradykinin. The cascade begins with contact activation: factor XII (Hageman factor) is activated when it contacts negatively charged surfaces, which in vivo include damaged subendothelium, exposed collagen, lipopolysaccharide, and foreign surfaces such as dialysis membranes. Activated factor XII (factor XIIa) then converts prekallikrein (which circulates in plasma as a complex bound to HMWK) to plasma kallikrein. Plasma kallikrein cleaves HMWK at two specific sites, releasing bradykinin — a nine-amino-acid peptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) — from the central portion of HMWK. A parallel tissue pathway exists in which tissue kallikrein cleaves low-molecular-weight kininogen (LMWK) to release kallidin (Lys-bradykinin), which can be converted to bradykinin by aminopeptidase.

• Option B: Option B is incorrect because mast cell tryptase does not directly cleave HMWK to generate bradykinin — tryptase amplifies inflammation through complement and protease-activated receptor activation, but it is not the enzyme responsible for HMWK cleavage in the kallikrein-kinin system; the plasma kallikrein cascade, not mast cell tryptase, is the primary bradykinin-generating pathway.
• Option C: Option C is incorrect because angiotensinogen is the precursor of angiotensin I, not bradykinin — the renin-angiotensin system and the kallikrein-kinin system are distinct pathways that share the enzyme ACE (which degrades bradykinin and converts angiotensin I to angiotensin II), but angiotensinogen cleavage does not produce bradykinin or a bradykinin precursor at any step.
• Option D: Option D is incorrect because complement C3a and C5a do not stimulate plasma kallikrein secretion from hepatocytes — plasma kallikrein is not secreted on demand from the liver in response to complement; it circulates as prekallikrein and is activated by factor XIIa in the contact activation pathway, a distinct cascade from complement activation despite the two systems interacting through tryptase and other shared proteases.
• Option E: Option E is incorrect because bradykinin is a peptide generated from a plasma protein by protease cleavage, not a lipid mediator generated from membrane phospholipids by phospholipase A2 — phospholipase A2 generates arachidonic acid for prostaglandin and leukotriene synthesis, an entirely different biochemical pathway; this distractor confuses peptide mediator synthesis with lipid mediator synthesis.

ANSWER: C

Rationale:

This question asked you to identify the principal bradykinin-degrading enzyme and explain why its inhibition has well-established clinical consequences. Angiotensin-converting enzyme (ACE), also called kininase II, is a zinc-containing dipeptidase expressed abundantly on the luminal surface of pulmonary vascular endothelium and in many other vascular beds. Its physiological substrates include angiotensin I (which it converts to angiotensin II) and bradykinin (from which it cleaves the C-terminal dipeptide Phe-Arg to generate an inactive fragment). Because ACE degrades bradykinin as a primary physiological function, inhibiting ACE with an ACE inhibitor (such as lisinopril, enalapril, or ramipril) blocks both angiotensin II production and bradykinin inactivation simultaneously. The resulting bradykinin accumulation in pulmonary and vascular tissues directly causes the two characteristic ACE inhibitor adverse effects: dry, nonproductive cough (bradykinin and substance P sensitization of bronchial C-fibers via B2 receptors) and angioedema (bradykinin-mediated B2 receptor activation increasing vascular permeability). This mechanistic relationship is the defining clinical teaching point of bradykinin pharmacology.

• Option A: Option A is incorrect because chymase is a mast cell serine protease with some bradykinin-degrading activity in tissue, but it is not the primary bradykinin-inactivating enzyme in plasma, which is dominated by ACE; inhibiting chymase is not associated with bradykinin accumulation as a clinically recognized adverse effect and does not cause cough or angioedema in the manner of ACE inhibitors.
• Option B: Option B is incorrect because while neprilysin does degrade bradykinin and sacubitril (the neprilysin inhibitor in sacubitril-valsartan) does cause some bradykinin accumulation, the statement that bradykinin effects are negligible with sacubitril is incorrect — sacubitril-valsartan carries a risk of bradykinin-mediated angioedema (which is why it is absolutely contraindicated within 36 hours of ACE inhibitor use), and neprilysin is a recognized secondary bradykinin-degrading pathway.
• Option D: Option D is incorrect in its characterization of des-Arg9-bradykinin as pharmacologically inert — des-Arg9-bradykinin is actually the primary endogenous agonist of the B1 receptor (not the B2 receptor), making it a pharmacologically active species rather than an inactive metabolite; carboxypeptidase N cleavage does not fully inactivate the bradykinin system but rather shifts activity toward B1 receptor-mediated effects, which are relevant in chronic inflammatory states.
• Option E: Option E is incorrect because DPP-4 inhibitors do not degrade bradykinin through DPP-4 — while DPP-4 inhibitors are associated with an increased risk of angioedema when combined with ACE inhibitors, this is attributed to competition for ACE-mediated bradykinin degradation rather than DPP-4-mediated bradykinin metabolism; DPP-4 is not a primary kininase.

ANSWER: E

Rationale:

This question asked you to characterize the B2 receptor's expression, signaling, and the functional consequences of its activation that account for bradykinin's role in acute vascular and pain responses. Unlike the B1 receptor (which is inducible and expressed at very low baseline levels), the B2 receptor is constitutively expressed and widely distributed throughout vascular endothelium, smooth muscle, sensory neurons, and other tissues — it is the receptor responsible for bradykinin's immediate physiological effects. The B2 receptor couples primarily to Gq, activating phospholipase C-beta, which generates inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release, which in vascular endothelium activates endothelial nitric oxide synthase (eNOS) through calmodulin — generating nitric oxide that diffuses to smooth muscle and produces potent vasodilation. Simultaneously, phospholipase A2 activation (downstream of Gq and calcium) generates arachidonic acid for prostacyclin (PGI2) synthesis via COX-1, contributing further to vasodilation and inhibiting platelet aggregation. In sensory C-fibers, B2 receptor activation directly depolarizes nociceptors and sensitizes TRPV1 channels through PKC-dependent phosphorylation — producing pain and hyperalgesia at inflammatory sites.

• Option A: Option A is incorrect because this description of inducibility, IL-1beta/TNF-alpha upregulation, and delayed expression describes the B1 receptor, not the B2 receptor; the B2 receptor is constitutively expressed and mediates acute effects, while B1 is the inducible receptor upregulated during chronic inflammation.
• Option B: Option B is incorrect because the B2 receptor is a G protein-coupled receptor, not a ligand-gated ion channel — it does not directly open calcium channels; the downstream calcium signal occurs through IP3-mediated intracellular calcium release from the endoplasmic reticulum, and eNOS activation is calmodulin-dependent, not calmodulin-independent.
• Option C: Option C is incorrect because the B2 receptor does not couple exclusively to Gs — its primary coupling is to Gq (phospholipase C activation), though Gi coupling also occurs in some contexts; the statement that B2 does not generate prostaglandins is incorrect, as prostacyclin synthesis from arachidonate is a well-established downstream consequence of B2 receptor activation in vascular endothelium.
• Option D: Option D is incorrect because the desensitization characteristics of B1 and B2 are described in reverse — it is the B2 receptor that desensitizes rapidly with continuous agonist exposure, while the B1 receptor does not desensitize readily, which is why B1 receptor signaling is sustained during chronic inflammatory states and why B1 has been investigated as a target for chronic pain therapy; B2 mediates acute rather than sustained inflammatory effects.

ANSWER: B

Rationale:

This question asked you to connect the B1 receptor's unique pharmacological properties to the clinical phenomenon of sustained bradykinin-mediated pain in chronic inflammation — a bridge question that applies concepts from the bradykinin physiology section to a specific research observation. The B1 receptor is normally expressed at very low levels in most tissues and makes a negligible contribution to bradykinin responses in the non-inflamed state. In inflamed tissue, however, the inflammatory cytokines IL-1beta and tumor necrosis factor-alpha (TNF-alpha) dramatically upregulate B1 receptor expression over hours. The B1 receptor's primary endogenous agonist is des-Arg9-bradykinin, the carboxypeptidase N cleavage product of bradykinin that represents an intermediate metabolite of bradykinin degradation rather than an inactive product. Crucially, unlike the B2 receptor (which desensitizes rapidly and ceases signaling with sustained agonist exposure), the B1 receptor does not desensitize — it continues to signal for as long as des-Arg9-bradykinin is present. This combination of upregulation by inflammation and resistance to desensitization makes the B1 receptor the molecular basis of sustained bradykinin-mediated pain in chronic inflammatory conditions, and it is an active target for novel analgesic drug development.

• Option A: Option A is incorrect because this description applies to the B1 receptor's properties, not the B2 receptor — it is the B2 receptor that desensitizes rapidly, and it does not undergo inflammatory conversion to a non-desensitizing form; PKC phosphorylation of B2 is involved in its downstream pain signaling (TRPV1 sensitization), not in preventing its desensitization.
• Option C: Option C is incorrect because the B1 receptor is not constitutively expressed at high levels in dorsal root ganglia — it is a low-baseline, inducible receptor that requires inflammatory cytokine stimulation for significant expression; describing it as constitutively expressed at high levels in sensory neurons reverses the defining characteristic that distinguishes B1 from B2.
• Option D: Option D is incorrect because bradykinin degradation by ACE and carboxypeptidase N is not abolished by the acidic pH of inflamed tissue — while local tissue pH at inflammatory sites does fall, both enzymes retain activity under the pH conditions encountered in vivo; furthermore, the sustained pain signal is receptor-mediated (through non-desensitizing B1 receptors and the B1 agonist des-Arg9-bradykinin), not simply due to bradykinin accumulation from enzyme inhibition.
• Option E: Option E is incorrect because prostaglandin E2 does sensitize nociceptors through EP2 and EP4 receptors (contributing to inflammatory hyperalgesia), but it does not upregulate B2 receptor gene transcription — B1 receptor (not B2) is the cytokine-inducible receptor, and the molecular mechanism of prostaglandin-mediated nociceptor sensitization involves cAMP elevation and ion channel phosphorylation rather than B-receptor transcriptional upregulation.

ANSWER: D

Rationale:

This question asked you to apply knowledge of the ACE inhibitor-bradykinin relationship to a classic clinical presentation and identify both the mechanism and the correct management. ACE inhibitor-induced cough is one of the most common drug adverse effects in primary care, occurring in approximately 5–15% of patients of European ancestry and up to 30–40% of patients of East Asian ancestry — making this patient's Chinese ancestry a relevant epidemiological detail. The mechanism is ACE inhibition reducing bradykinin degradation in the bronchial mucosa: bradykinin and substance P (which ACE also degrades) accumulate, stimulating B2 receptors on bronchial sensory C-fibers to release prostaglandins and directly activate TRPV1 ion channels, producing the characteristic dry, nonproductive cough that does not respond to antitussives, antihistamines, or corticosteroids. The cough resolves within days to weeks of stopping the ACE inhibitor. The correct management is switching to an ARB (such as losartan, valsartan, or irbesartan), which blocks the angiotensin II receptor downstream of ACE without inhibiting ACE itself and therefore without causing bradykinin accumulation — ARBs retain the nephroprotective benefit in diabetic nephropathy without causing the cough.

• Option A: Option A is incorrect because ACEI cough is bradykinin-mediated, not histamine-mediated — H1 antihistamines do not suppress this cough and there is no role for loratadine or any antihistamine in treating or suppressing ACEI-induced cough; the bronchial C-fiber stimulation bypasses the histamine receptor pathway entirely.
• Option B: Option B is incorrect because lisinopril does not downregulate beta-2 adrenergic receptors — ACE inhibitors have no adrenergic receptor effects; and the claim that ARBs share the cough mechanism is incorrect because ARBs do not inhibit ACE and therefore do not cause bradykinin accumulation or ACEI-type cough in most patients.
• Option C: Option C is incorrect because ACEI cough is a class effect of ACE inhibitors specifically (not all antihypertensives), the mechanism is drug-induced bradykinin accumulation (not a baseline ACE gene polymorphism independent of drug therapy), and the cough does not resolve spontaneously with continued therapy — it persists as long as the ACE inhibitor is used and resolves only after discontinuation.
• Option E: Option E is incorrect because ACEI cough is not caused by angiotensin II deficiency or its effects on bronchial mucus glands — the mechanism is bradykinin accumulation at C-fibers, not angiotensin II-dependent mucus secretion; there is no approved angiotensin II receptor agonist for this indication, and this mechanism is pharmacologically fictitious.

ANSWER: A

Rationale:

This question asked you to apply the mechanistic distinction between bradykinin-mediated and histamine-mediated angioedema to a high-acuity clinical emergency. ACE inhibitor-induced angioedema is caused by bradykinin accumulation at dermal and submucosal microvasculature — bradykinin activates B2 receptors on vascular endothelium, generating nitric oxide and prostacyclin that increase vascular permeability and cause tissue edema. Because the mediator is bradykinin and not histamine, the standard anaphylaxis management protocol — epinephrine, antihistamines, and corticosteroids — has limited and unpredictable efficacy; these agents address histamine-mediated effects, not bradykinin-driven permeability. Laryngeal and tongue involvement (evidenced by stridor and SpO2 of 94%) signals a potentially fatal airway emergency. The swelling does not reverse rapidly with epinephrine as it would in histamine-mediated anaphylaxis, and clinicians who rely on standard anaphylaxis agents may find the airway continues to compromise while they wait for an effect that is not coming. Early definitive airway management — intubation or surgical airway — is required before swelling progresses to complete obstruction. The ACEI must be permanently discontinued; rechallenge is absolutely contraindicated. African American race is associated with a three- to fivefold higher risk of ACEI angioedema compared to White patients.

• Option B: Option B is incorrect because ACEI angioedema is bradykinin-mediated, not histamine-mediated — epinephrine does not reliably reduce bradykinin-driven permeability, and expecting visible tongue reduction within 10–15 minutes of epinephrine reflects the mistaken assumption that this is histamine-mediated anaphylaxis; enalapril does not inhibit prostaglandin synthesis and this mechanism is pharmacologically incorrect.
• Option C: Option C is incorrect because the absence of urticaria is actually the defining clinical feature of bradykinin-mediated angioedema (both ACEI-induced and hereditary), not a reason to exclude enalapril as the cause — urticaria accompanies histamine-mediated events; ACEI is among the most common causes of angioedema without urticaria, and the patient's enalapril use is a strongly positive exposure history; withholding treatment to test C1 inhibitor levels in an actively stridor-compromised airway is dangerous.
• Option D: Option D is incorrect because ACE inhibitor-induced angioedema is not managed by adding an H2 blocker — it is not H2 receptor-mediated, and famotidine has no effect on bradykinin-mediated vascular permeability; enalapril must be permanently discontinued and is not a dose-dependent effect that self-resolves with receptor saturation.
• Option E: Option E is incorrect because stridor in this setting indicates upper airway swelling of the larynx and tongue compressing the airway — not lower airway bronchospasm — and albuterol addresses bronchospasm of the small airways, not the mechanical obstruction caused by laryngeal and lingual soft tissue edema; beta-2 agonists will not reduce supraglottic tissue swelling.

ANSWER: C

Rationale:

This question asked you to connect the mechanism of neprilysin inhibition to the ACE inhibitor-bradykinin relationship and explain the clinical consequence of simultaneous inhibition of both bradykinin-degrading pathways. Sacubitril-valsartan (Entresto) combines sacubitril (a neprilysin inhibitor) with valsartan (an ARB). Neprilysin is one of the enzymes that degrades bradykinin in the circulation and vascular tissue; by inhibiting neprilysin, sacubitril raises bradykinin levels to a degree that is manageable when the other major bradykinin-degrading enzyme (ACE) remains active. However, when sacubitril-valsartan is initiated while an ACE inhibitor such as lisinopril is still present at effective plasma concentrations, both major bradykinin degradation pathways are simultaneously blocked: neprilysin by sacubitril and ACE (kininase II) by lisinopril. The resulting bradykinin accumulation substantially increases the risk of bradykinin-mediated angioedema, which may involve the tongue, larynx, and pharynx and can be life-threatening. For this reason, sacubitril-valsartan is absolutely contraindicated within 36 hours of the last dose of any ACE inhibitor — a specific regulatory requirement based on this pharmacological interaction. In this patient, whose last lisinopril dose was 18 hours ago, initiating sacubitril-valsartan must be delayed.

• Option A: Option A is incorrect because sacubitril does not require ACE for its activation — sacubitril is hydrolyzed to its active neprilysin inhibitor form (LBQ657) by esterases, not by ACE; the washout period is required for safety reasons related to bradykinin accumulation, not for pharmacokinetic activation reasons.
• Option B: Option B is incorrect because ACE inhibitors and ARBs do not compete for the same binding site — lisinopril inhibits the ACE enzyme (a dipeptidase), while valsartan blocks the AT1 angiotensin II receptor (a GPCR); they act at pharmacologically distinct targets; while combining ACE inhibitors and ARBs does increase the risk of hyperkalemia and AKI, this is not the basis for the specific 36-hour contraindication with sacubitril-valsartan.
• Option D: Option D is incorrect because sacubitril-valsartan does not inhibit the OAT1 transporter responsible for lisinopril renal secretion; lisinopril accumulation from transporter inhibition is not the mechanism of the interaction and this pharmacokinetic scenario is not the basis for the contraindication.
• Option E: Option E is incorrect because the 36-hour washout is not simply a combined half-life calculation or a pharmacokinetic clearance interval without pharmacodynamic significance — it is specifically required because of the dangerous bradykinin-mediated angioedema risk when both enzymes are simultaneously inhibited; describing the interaction as "no specific risk beyond additive antihypertensive effect" is clinically incorrect and understates a potentially fatal drug interaction.

ANSWER: E

Rationale:

This question asked you to apply knowledge of the C1 inhibitor's role in the kallikrein-kinin system to identify hereditary angioedema and explain why standard allergy therapy fails. The clinical features are characteristic of hereditary angioedema (HAE): episodic non-urticarial swelling lasting days (longer than typical allergic angioedema), absence of allergen trigger, complete failure of epinephrine and antihistamines to produce relief, and a positive family history consistent with autosomal dominant inheritance. C1 inhibitor (C1-INH) is a serine protease inhibitor (serpin) that normally restrains the contact activation system by inhibiting activated factor XII (factor XIIa), plasma kallikrein, and factor XI. In HAE type I (which accounts for approximately 85% of cases), C1-INH antigen and function are both reduced — as in this patient whose C1-INH antigen is at 18% of normal. Without adequate C1-INH, plasma kallikrein operates without restraint and generates bradykinin continuously from HMWK through the contact activation cascade. The resulting bradykinin excess causes episodic subcutaneous and submucosal edema at the extremities, abdomen, face, and upper airway. Because histamine plays no role in the mediator cascade, antihistamines and corticosteroids are ineffective; because bradykinin-mediated permeability is driven by NO and prostacyclin rather than adrenergic vasoconstriction-reversible pathways, epinephrine has limited and unpredictable efficacy. Acute HAE treatment requires agents targeting the kallikrein-kinin system directly: icatibant (B2 receptor antagonist), ecallantide (kallikrein inhibitor), C1-INH concentrate, or recombinant C1-INH.

• Option A: Option A is incorrect because the presentation is definitively not IgE-mediated allergic angioedema — the absence of urticaria, the failure of epinephrine and antihistamines, and the autosomal dominant family history all argue against an IgE-mediated mechanism; attributing low C1-INH to prevention of antihistamine tissue penetration is pharmacologically fictitious.
• Option B: Option B is incorrect because acquired C1-INH deficiency from B-cell lymphoproliferative disease (HAE type II acquired form) typically presents in adults over 40 with no family history, as C1-INH consumption is secondary to monoclonal protein or lymphoma — a 28-year-old with a positive family history and early-onset recurrent attacks has hereditary, not acquired, disease; the statement that acquired disease "does not run in families" while hereditary does is inverted in the distractor description.
• Option C: Option C is incorrect because HAE type II (dysfunctional C1-INH at normal antigen levels) would present with normal or elevated antigen on ELISA but reduced C1-INH functional activity — this patient has markedly low antigen at 18% of normal, which is diagnostic for type I HAE (reduced antigen and reduced function), not type II; the option's conclusion that low antigen "excludes type II HAE by definition" is correct but the initial premise misclassifies the presented case.
• Option D: Option D is incorrect because C1q autoantibody-mediated complement consumption is associated with systemic lupus erythematosus and some vasculitides, not with the clinical picture described here; eculizumab targets C5 in complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria, not the kallikrein-kinin system, and would not address bradykinin overproduction from kallikrein dysregulation.

ANSWER: B

Rationale:

This question asked you to demonstrate understanding of omalizumab's primary and secondary mechanisms, connect the two mechanistically, and reason about why the observed rapid clinical response in CSU implies additional pharmacological activity beyond the established primary pathway. Omalizumab binds free circulating IgE at the Fc-epsilon-III domain, preventing IgE from occupying Fc-epsilon-RI receptors on mast cells. Over weeks to months, as free IgE in plasma falls, the amount of IgE occupying mast cell surface Fc-epsilon-RI decreases. Because Fc-epsilon-RI receptor expression on mast cells is transcriptionally and translationally upregulated by surface IgE occupancy (IgE acts as a receptor stabilizer — without IgE in the binding site, the receptor is not retained at the cell surface), reduced surface IgE leads to Fc-epsilon-RI down-regulation over time. This secondary mechanism requires weeks to months to be fully established. However, many CSU patients respond within 1–4 weeks — faster than this secondary mechanism alone predicts. Proposed explanations include reduction of autoimmune IgE (some CSU involves IgE directed against Fc-epsilon-RI itself or against autoantigens such as thyroperoxidase), and direct mast cell stabilization by omalizumab independent of specific IgE-antigen interactions. This mechanistic uncertainty is clinically acknowledged and does not undermine the drug's proven efficacy.

• Option A: Option A is incorrect because omalizumab does not cross-link Fc-epsilon-RI receptors directly or trigger receptor endocytosis — it binds free IgE in plasma, not receptor-bound IgE on mast cell surfaces; receptor down-regulation occurs secondarily as surface IgE falls and receptor maintenance signaling decreases, not from direct receptor cross-linking or omalizumab-mediated endocytosis.
• Option C: Option C is incorrect because omalizumab physically cannot bind to IgE that is already occupying the Fc-epsilon-RI receptor — the Fc-epsilon-III domain is buried in the receptor-IgE interface and is inaccessible when IgE is receptor-bound; steric blocking of allergen access is not the mechanism of omalizumab, which operates exclusively on free IgE in circulation before it reaches the mast cell surface.
• Option D: Option D is incorrect because omalizumab does not bind or inhibit tryptase — it is an anti-IgE antibody with no known direct interaction with mast cell proteases; tryptase inhibition is not a described mechanism of omalizumab and would represent an entirely different pharmacological target.
• Option E: Option E is incorrect because omalizumab does not bind to Fc-epsilon-RI receptors directly or allosterically — it binds to the IgE molecule itself at the Fc-epsilon-III domain; the concept of a separate allosteric receptor site for omalizumab is pharmacologically incorrect and does not reflect the drug's established mechanism.

ANSWER: D

Rationale:

This question asked you to integrate the CYP inhibition pharmacology of cimetidine — established in the opening questions of this set — with its clinical consequence in a patient on a narrow-therapeutic-index anticoagulant, completing the bridge from mechanism to patient outcome. Warfarin is a racemic mixture administered as the S-enantiomer and R-enantiomer; the S-enantiomer is approximately 3–5 times more pharmacologically active as a vitamin K epoxide reductase inhibitor and is metabolized primarily by CYP2C9. Cimetidine inhibits CYP2C9 (along with CYP1A2, CYP2C19, CYP2D6, and CYP3A4) through coordination of its imidazole ring nitrogen with the CYP heme iron — a competitive inhibition mechanism that reduces the enzymatic clearance of S-warfarin. As S-warfarin accumulates, its anticoagulant effect intensifies, raising the INR above the therapeutic range and causing the bleeding seen here. Famotidine lacks the imidazole ring and does not inhibit CYP2C9 at therapeutic doses; prescribing famotidine (or nizatidine) instead would have avoided this interaction entirely. This case illustrates why the H2RA drug-interaction profile must be considered before prescribing, not corrected retrospectively after a bleeding event.

• Option A: Option A is incorrect because cimetidine is not a clinically significant P-glycoprotein inhibitor, and the warfarin drug interaction occurs through hepatic CYP inhibition, not through increased intestinal absorption; famotidine is not a P-gp inducer and does not reduce warfarin absorption through this mechanism.
• Option B: Option B is incorrect because plasma protein displacement interactions — while theoretically possible — rarely produce clinically significant effects in isolation because the displaced drug is simultaneously available for distribution and elimination; the primary mechanism of the cimetidine-warfarin interaction is CYP2C9 inhibition reducing warfarin metabolism, not albumin displacement; protein-displacement interactions have historically been overemphasized as a mechanism for clinical drug interactions and are not the correct explanation here.
• Option C: Option C is incorrect because S-warfarin is not cleared primarily by CYP2C19-mediated glucuronide conjugation — its primary metabolic pathway is CYP2C9-mediated oxidative ring hydroxylation (Phase I), not Phase II glucuronidation; and the claim that famotidine shares the imidazole pharmacophore is incorrect — famotidine does not contain an imidazole ring, which is precisely why it does not inhibit CYP enzymes, making it safe in warfarin-treated patients.
• Option E: Option E is incorrect because cimetidine does not inhibit vitamin K epoxide reductase — warfarin inhibits VKOR and cimetidine enhances warfarin's effect indirectly by reducing its CYP2C9-mediated clearance, not by directly inhibiting the same enzymatic target; and the claim that VKOR inhibition is a class effect of all H2RAs is false — no H2 receptor antagonist inhibits VKOR, and famotidine is safe in warfarin-treated patients precisely because it does not alter warfarin's pharmacokinetics or pharmacodynamics.